SIMILAR PATTERN OF AMINO ACIDS MAPPED TO 'XZN'


List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)
Filter list by:
DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 Interface HETATM RMSD Dali
Z-score		 Seq.
Identity (%)		 View Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1IEP_A_STIA201_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		8 / 12 LEU A  42
VAL A  50
ALA A  63
GLU A  81
PHE A 112
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.75A 1iepA-4bc6A:
21.7		 1iepA-4bc6A:
28.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1IEP_B_STIB202_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 LEU A  42
VAL A  50
ALA A  63
GLU A  81
PHE A 112
GLY A 116
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 ( 4.3A)
 0.76A 1iepB-4bc6A:
21.7		 1iepB-4bc6A:
28.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1IEP_B_STIB202_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 LEU A  42
VAL A  50
ALA A  63
ILE A  84
PHE A 112
GLY A 116
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
None
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 ( 4.3A)
 0.97A 1iepB-4bc6A:
21.7		 1iepB-4bc6A:
28.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1IEP_B_STIB202_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		4 / 7 LYS A  65
VAL A  94
ILE A 108
LEU A 164
 XZN  A1317 (-4.1A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.7A)
 0.59A 1iepB-4bc6A:
21.7		 1iepB-4bc6A:
28.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1OPJ_A_STIA3_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 12 LEU A  42
VAL A  50
ALA A  63
VAL A  94
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.61A 1opjA-4bc6A:
21.2		 1opjA-4bc6A:
28.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1OPJ_A_STIA3_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 12 LEU A  42
VAL A  50
ALA A  63
VAL A  94
PHE A 112
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 4.3A)
 0.50A 1opjA-4bc6A:
21.2		 1opjA-4bc6A:
28.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1OPJ_B_STIB4_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 VAL A  50
ALA A  63
GLU A  81
VAL A  94
PHE A 112
GLY A 116
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 ( 4.3A)
 0.77A 1opjB-4bc6A:
21.3		 1opjB-4bc6A:
28.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UWH_A_BAXA1723_1
(B-RAF PROTO-ONCOGENE
SERINE/THREONINE-PRO
TEIN KINASE)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 12 ALA A  63
GLU A  81
LEU A  85
CYH A 113
LEU A 148
HIS A 155
 XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
None
XZN  A1317 (-3.7A)
None
None
 0.67A 1uwhA-4bc6A:
22.3		 1uwhA-4bc6A:
28.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UWH_B_BAXB1723_1
(B-RAF PROTO-ONCOGENE
SERINE/THREONINE-PRO
TEIN KINASE)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 12 ALA A  63
GLU A  81
LEU A  85
CYH A 113
LEU A 148
HIS A 155
 XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
None
XZN  A1317 (-3.7A)
None
None
 0.67A 1uwhB-4bc6A:
22.1		 1uwhB-4bc6A:
28.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UWJ_A_BAXA1723_1
(B-RAF PROTO-ONCOGENE
SERINE/THREONINE-PRO
TEIN KINASE)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 12 VAL A  50
ALA A  63
GLU A  81
CYH A 113
LEU A 148
HIS A 155
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-3.7A)
None
None
 0.74A 1uwjA-4bc6A:
22.0		 1uwjA-4bc6A:
28.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UWJ_B_BAXB1723_1
(B-RAF PROTO-ONCOGENE
SERINE/THREONINE-PRO
TEIN KINASE)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 12 VAL A  50
ALA A  63
GLU A  81
CYH A 113
LEU A 148
HIS A 155
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-3.7A)
None
None
 0.74A 1uwjB-4bc6A:
22.0		 1uwjB-4bc6A:
28.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XBB_A_STIA1_1
(TYROSINE-PROTEIN
KINASE SYK)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		5 / 9 LEU A  42
VAL A  50
ALA A  63
GLY A 116
LEU A 164
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
 0.48A 1xbbA-4bc6A:
23.0		 1xbbA-4bc6A:
25.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GQG_A_1N1A501_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 LEU A  42
ALA A  63
GLU A  81
VAL A  94
ILE A 108
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.85A 2gqgA-4bc6A:
23.0		 2gqgA-4bc6A:
29.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GQG_A_1N1A501_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		9 / 12 LEU A  42
ALA A  63
LYS A  65
VAL A  94
ILE A 108
PHE A 112
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.1A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.89A 2gqgA-4bc6A:
23.0		 2gqgA-4bc6A:
29.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GQG_B_1N1B502_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		8 / 12 LEU A  42
ALA A  63
GLU A  81
VAL A  94
ILE A 108
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.4A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.75A 2gqgB-4bc6A:
13.6		 2gqgB-4bc6A:
29.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GQG_B_1N1B502_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		8 / 12 LEU A  42
VAL A  50
ALA A  63
VAL A  94
ILE A 108
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.4A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.65A 2gqgB-4bc6A:
13.6		 2gqgB-4bc6A:
29.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HYY_A_STIA600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 VAL A  50
ALA A  63
GLU A  81
PHE A 112
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.74A 2hyyA-4bc6A:
21.8		 2hyyA-4bc6A:
29.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HYY_A_STIA600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 VAL A  50
ALA A  63
ILE A  84
PHE A 112
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
None
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 1.01A 2hyyA-4bc6A:
21.8		 2hyyA-4bc6A:
29.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HYY_A_STIA600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		4 / 6 LEU A  42
LYS A  65
VAL A  94
ILE A 108
 XZN  A1317 (-3.6A)
XZN  A1317 (-4.1A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.4A)
 0.86A 2hyyA-4bc6A:
21.8		 2hyyA-4bc6A:
29.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HYY_B_STIB600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 VAL A  50
ALA A  63
GLU A  81
PHE A 112
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.72A 2hyyB-4bc6A:
21.9		 2hyyB-4bc6A:
29.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HYY_B_STIB600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 VAL A  50
ALA A  63
ILE A  84
PHE A 112
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
None
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 1.00A 2hyyB-4bc6A:
21.9		 2hyyB-4bc6A:
29.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HYY_C_STIC600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		8 / 12 VAL A  50
ALA A  63
GLU A  81
VAL A  94
PHE A 112
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.61A 2hyyC-4bc6A:
22.1		 2hyyC-4bc6A:
29.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HYY_C_STIC600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 VAL A  50
ALA A  63
ILE A  84
PHE A 112
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
None
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 1.01A 2hyyC-4bc6A:
22.1		 2hyyC-4bc6A:
29.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HYY_D_STID600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 VAL A  50
ALA A  63
GLU A  81
ILE A 108
PHE A 112
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.5A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.75A 2hyyD-4bc6A:
21.7		 2hyyD-4bc6A:
29.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HYY_D_STID600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 VAL A  50
ALA A  63
ILE A  84
ILE A 108
PHE A 112
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
None
XZN  A1317 (-4.4A)
XZN  A1317 (-4.5A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 1.08A 2hyyD-4bc6A:
21.7		 2hyyD-4bc6A:
29.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2OIQ_A_STIA1001_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 VAL A  50
ALA A  63
GLU A  81
ILE A 108
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.4A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.66A 2oiqA-4bc6A:
21.5		 2oiqA-4bc6A:
24.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2PL0_A_STIA200_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 VAL A  50
ALA A  63
GLU A  81
VAL A  94
ILE A 108
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.83A 2pl0A-4bc6A:
20.8		 2pl0A-4bc6A:
25.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2PL0_A_STIA200_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 VAL A  50
ALA A  63
LYS A  65
VAL A  94
ILE A 108
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.1A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.94A 2pl0A-4bc6A:
20.8		 2pl0A-4bc6A:
25.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2ZVA_A_1N1A513_1
(TYROSINE-PROTEIN
KINASE LYN)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		8 / 12 LEU A  42
ALA A  63
GLU A  81
VAL A  94
ILE A 108
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.4A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.87A 2zvaA-4bc6A:
23.8		 2zvaA-4bc6A:
25.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3C7Q_A_XINA1172_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		8 / 12 LEU A  42
GLY A  43
ALA A  63
VAL A  94
PHE A 112
CYH A 113
GLY A 116
LEU A 164
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.9A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.5A)
XZN  A1317 (-3.7A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
 0.60A 3c7qA-4bc6A:
20.4		 3c7qA-4bc6A:
27.61
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_A_NILA600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 10 LEU A  42
VAL A  50
LYS A  65
VAL A  94
ILE A 108
PHE A 112
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-4.1A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.5A)
 0.69A 3cs9A-4bc6A:
21.6		 3cs9A-4bc6A:
30.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_B_NILB600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 9 LEU A  42
VAL A  50
LYS A  65
VAL A  94
ILE A 108
LEU A 164
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-4.1A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.7A)
 0.75A 3cs9B-4bc6A:
22.3		 3cs9B-4bc6A:
30.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_C_NILC600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		5 / 12 ALA A  63
GLU A  81
PHE A 112
HIS A 155
ALA A 174
 XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.5A)
None
XZN  A1317 ( 4.3A)
 0.83A 3cs9C-4bc6A:
21.8		 3cs9C-4bc6A:
30.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_C_NILC600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		5 / 12 ALA A  63
ILE A  84
PHE A 112
HIS A 155
ALA A 174
 XZN  A1317 (-3.5A)
None
XZN  A1317 (-4.5A)
None
XZN  A1317 ( 4.3A)
 0.89A 3cs9C-4bc6A:
21.8		 3cs9C-4bc6A:
30.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_C_NILC600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		5 / 9 LEU A  42
VAL A  50
LYS A  65
VAL A  94
ILE A 108
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-4.1A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.4A)
 0.80A 3cs9C-4bc6A:
21.8		 3cs9C-4bc6A:
30.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_D_NILD600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		5 / 12 ALA A  63
PHE A 112
GLY A 116
HIS A 155
ALA A 174
 XZN  A1317 (-3.5A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
None
XZN  A1317 ( 4.3A)
 0.48A 3cs9D-4bc6A:
20.9		 3cs9D-4bc6A:
30.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_D_NILD600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		4 / 6 LEU A  42
VAL A  50
LYS A  65
LEU A 164
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-4.1A)
XZN  A1317 (-4.7A)
 0.68A 3cs9D-4bc6A:
20.9		 3cs9D-4bc6A:
30.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3G0F_A_B49A9001_1
(MAST/STEM CELL
GROWTH FACTOR
RECEPTOR)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 11 LEU A  42
VAL A  50
ALA A  63
CYH A 113
GLY A 116
LEU A 164
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.7A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
 0.74A 3g0fA-4bc6A:
20.9		 3g0fA-4bc6A:
28.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3G0F_B_B49B9001_1
(MAST/STEM CELL
GROWTH FACTOR
RECEPTOR)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 10 LEU A  42
VAL A  50
ALA A  63
CYH A 113
GLY A 116
LEU A 164
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.7A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
 0.75A 3g0fB-4bc6A:
21.2		 3g0fB-4bc6A:
28.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3G5D_A_1N1A1_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		8 / 12 LEU A  42
VAL A  50
ALA A  63
VAL A  94
ILE A 108
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.4A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.81A 3g5dA-4bc6A:
22.7		 3g5dA-4bc6A:
24.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3GVU_A_STIA1001_1
(TYROSINE-PROTEIN
KINASE ABL2)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 LEU A  42
VAL A  50
ALA A  63
GLU A  81
VAL A  94
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.69A 3gvuA-4bc6A:
21.8		 3gvuA-4bc6A:
28.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3GVU_A_STIA1001_1
(TYROSINE-PROTEIN
KINASE ABL2)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 LEU A  42
VAL A  50
ALA A  63
ILE A  84
VAL A  94
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
None
XZN  A1317 (-4.4A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 1.05A 3gvuA-4bc6A:
21.8		 3gvuA-4bc6A:
28.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3IK3_A_0LIA1_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 12 ALA A  63
GLU A  81
VAL A  94
ILE A 110
LEU A 164
ALA A 174
 XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.4A)
XZN  A1317 (-3.3A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.63A 3ik3A-4bc6A:
21.8		 3ik3A-4bc6A:
29.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3IK3_A_0LIA1_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 12 ALA A  63
VAL A  94
ILE A 110
HIS A 155
LEU A 164
ALA A 174
 XZN  A1317 (-3.5A)
XZN  A1317 (-4.4A)
XZN  A1317 (-3.3A)
None
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.58A 3ik3A-4bc6A:
21.8		 3ik3A-4bc6A:
29.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3IK3_B_0LIB2_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 12 ALA A  63
GLU A  81
VAL A  94
ILE A 110
LEU A 164
ALA A 174
 XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.4A)
XZN  A1317 (-3.3A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.73A 3ik3B-4bc6A:
21.5		 3ik3B-4bc6A:
29.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3IK3_B_0LIB2_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 12 ALA A  63
VAL A  94
ILE A 110
HIS A 155
LEU A 164
ALA A 174
 XZN  A1317 (-3.5A)
XZN  A1317 (-4.4A)
XZN  A1317 (-3.3A)
None
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.72A 3ik3B-4bc6A:
21.5		 3ik3B-4bc6A:
29.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3K54_A_1N1A1_1
(TYROSINE-PROTEIN
KINASE BTK)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 LEU A  42
ALA A  63
GLU A  81
VAL A  94
ILE A 108
GLY A 116
LEU A 164
 XZN  A1317 (-3.6A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.4A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
 0.73A 3k54A-4bc6A:
22.0		 3k54A-4bc6A:
26.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3K5V_A_STIA2_1
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 VAL A  50
ALA A  63
GLU A  81
PHE A 112
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.74A 3k5vA-4bc6A:
21.2		 3k5vA-4bc6A:
28.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3K5V_A_STIA2_1
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 VAL A  50
ALA A  63
ILE A  84
PHE A 112
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
None
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.98A 3k5vA-4bc6A:
21.2		 3k5vA-4bc6A:
28.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3K5V_B_STIB2_1
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 VAL A  50
ALA A  63
GLU A  81
PHE A 112
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.69A 3k5vB-4bc6A:
21.2		 3k5vB-4bc6A:
28.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3K5V_B_STIB2_1
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 VAL A  50
ALA A  63
ILE A  84
PHE A 112
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
None
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.97A 3k5vB-4bc6A:
21.2		 3k5vB-4bc6A:
28.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MIY_A_B49A1_1
(TYROSINE-PROTEIN
KINASE ITK/TSK)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 11 ALA A  63
VAL A  94
PHE A 112
GLY A 116
LEU A 164
ASP A 175
 XZN  A1317 (-3.5A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 (-3.2A)
 0.59A 3miyA-4bc6A:
22.2		 3miyA-4bc6A:
28.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MS9_A_STIA1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 LEU A  42
VAL A  50
ALA A  63
GLU A  81
PHE A 112
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.5A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.76A 3ms9A-4bc6A:
21.4		 3ms9A-4bc6A:
28.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MS9_A_STIA1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 LEU A  42
VAL A  50
ALA A  63
ILE A  84
PHE A 112
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
None
XZN  A1317 (-4.5A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.94A 3ms9A-4bc6A:
21.4		 3ms9A-4bc6A:
28.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MS9_B_STIB1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		8 / 12 LEU A  42
VAL A  50
ALA A  63
GLU A  81
PHE A 112
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.72A 3ms9B-4bc6A:
21.5		 3ms9B-4bc6A:
28.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MS9_B_STIB1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		8 / 12 LEU A  42
VAL A  50
ALA A  63
ILE A  84
PHE A 112
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
None
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.91A 3ms9B-4bc6A:
21.5		 3ms9B-4bc6A:
28.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MSS_A_STIA1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 LEU A  42
VAL A  50
ALA A  63
GLU A  81
PHE A 112
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.5A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.79A 3mssA-4bc6A:
21.5		 3mssA-4bc6A:
28.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MSS_A_STIA1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 LEU A  42
VAL A  50
ALA A  63
ILE A  84
PHE A 112
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
None
XZN  A1317 (-4.5A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.97A 3mssA-4bc6A:
21.5		 3mssA-4bc6A:
28.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MSS_B_STIB1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 LEU A  42
VAL A  50
ALA A  63
PHE A 112
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.61A 3mssB-4bc6A:
21.5		 3mssB-4bc6A:
28.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MSS_B_STIB1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 VAL A  50
ALA A  63
GLU A  81
PHE A 112
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.74A 3mssB-4bc6A:
21.5		 3mssB-4bc6A:
28.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MSS_C_STIC1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 LEU A  42
VAL A  50
ALA A  63
GLU A  81
PHE A 112
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.5A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.79A 3mssC-4bc6A:
21.5		 3mssC-4bc6A:
28.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MSS_C_STIC1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 LEU A  42
VAL A  50
ALA A  63
ILE A  84
PHE A 112
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
None
XZN  A1317 (-4.5A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.97A 3mssC-4bc6A:
21.5		 3mssC-4bc6A:
28.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MSS_D_STID1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 LEU A  42
ALA A  63
GLU A  81
PHE A 112
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.75A 3mssD-4bc6A:
21.5		 3mssD-4bc6A:
28.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MSS_D_STID1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 LEU A  42
ALA A  63
ILE A  84
PHE A 112
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 (-3.5A)
None
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.92A 3mssD-4bc6A:
21.5		 3mssD-4bc6A:
28.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MSS_D_STID1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		4 / 6 VAL A  50
LYS A  65
VAL A  94
ILE A 108
 XZN  A1317 ( 4.7A)
XZN  A1317 (-4.1A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.4A)
 0.89A 3mssD-4bc6A:
21.5		 3mssD-4bc6A:
28.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OEZ_A_STIA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 VAL A  50
ALA A  63
GLU A  81
VAL A  94
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.4A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.61A 3oezA-4bc6A:
21.5		 3oezA-4bc6A:
24.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OEZ_B_STIB601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 VAL A  50
ALA A  63
LYS A  65
GLU A  81
ILE A 108
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.1A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.79A 3oezB-4bc6A:
21.7		 3oezB-4bc6A:
24.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OXZ_A_0LIA1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 12 ALA A  63
GLU A  81
VAL A  94
GLY A 116
HIS A 155
ALA A 174
 XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.4A)
XZN  A1317 ( 3.7A)
None
XZN  A1317 ( 4.3A)
 0.58A 3oxzA-4bc6A:
20.2		 3oxzA-4bc6A:
29.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3PYY_A_STIA3_1
(V-ABL ABELSON MURINE
LEUKEMIA VIRAL
ONCOGENE HOMOLOG 1
ISOFORM B VARIANT)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 12 LEU A  42
VAL A  50
ALA A  63
PHE A 112
GLY A 116
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 ( 4.3A)
 0.74A 3pyyA-4bc6A:
21.8		 3pyyA-4bc6A:
29.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3PYY_A_STIA3_1
(V-ABL ABELSON MURINE
LEUKEMIA VIRAL
ONCOGENE HOMOLOG 1
ISOFORM B VARIANT)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 12 VAL A  50
ALA A  63
GLU A  81
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.75A 3pyyA-4bc6A:
21.8		 3pyyA-4bc6A:
29.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3PYY_A_STIA3_1
(V-ABL ABELSON MURINE
LEUKEMIA VIRAL
ONCOGENE HOMOLOG 1
ISOFORM B VARIANT)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 12 VAL A  50
ALA A  63
GLU A  81
PHE A 112
GLY A 116
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 ( 4.3A)
 0.76A 3pyyA-4bc6A:
21.8		 3pyyA-4bc6A:
29.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3PYY_B_STIB4_1
(V-ABL ABELSON MURINE
LEUKEMIA VIRAL
ONCOGENE HOMOLOG 1
ISOFORM B VARIANT)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 LEU A  42
VAL A  50
ALA A  63
GLU A  81
VAL A  94
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.72A 3pyyB-4bc6A:
21.5		 3pyyB-4bc6A:
29.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3QLG_B_1N1B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		9 / 12 LEU A  42
VAL A  50
ALA A  63
GLU A  81
VAL A  94
GLY A 116
LEU A 164
ALA A 174
ASP A 175
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.4A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
XZN  A1317 (-3.2A)
 0.81A 3qlgB-4bc6A:
22.6		 3qlgB-4bc6A:
24.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RGF_A_BAXA465_1
(CYCLIN-DEPENDENT
KINASE 8)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 VAL A  50
ALA A  63
GLU A  81
LEU A  85
LEU A 148
HIS A 155
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
None
None
None
XZN  A1317 ( 4.3A)
 0.75A 3rgfA-4bc6A:
13.9		 3rgfA-4bc6A:
24.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3SXR_A_1N1A1_1
(CYTOPLASMIC
TYROSINE-PROTEIN
KINASE BMX)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 LEU A  42
VAL A  50
ALA A  63
VAL A  94
ILE A 108
GLY A 116
LEU A 164
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.4A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
 0.64A 3sxrA-4bc6A:
22.5		 3sxrA-4bc6A:
29.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UE4_A_DB8A601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 LEU A  42
ALA A  63
GLU A  81
ILE A 108
PHE A 112
GLY A 116
LEU A 164
 XZN  A1317 (-3.6A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
 0.86A 3ue4A-4bc6A:
22.7		 3ue4A-4bc6A:
29.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UE4_A_DB8A601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		8 / 12 LEU A  42
ALA A  63
LYS A  65
VAL A  94
ILE A 108
PHE A 112
GLY A 116
LEU A 164
 XZN  A1317 (-3.6A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.1A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
 0.78A 3ue4A-4bc6A:
22.7		 3ue4A-4bc6A:
29.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UE4_B_DB8B601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		8 / 12 LEU A  42
VAL A  50
ALA A  63
GLU A  81
ILE A 108
PHE A 112
GLY A 116
LEU A 164
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
 0.83A 3ue4B-4bc6A:
22.6		 3ue4B-4bc6A:
29.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UE4_B_DB8B601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		8 / 12 LEU A  42
VAL A  50
ALA A  63
VAL A  94
ILE A 108
PHE A 112
GLY A 116
LEU A 164
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
 0.67A 3ue4B-4bc6A:
22.6		 3ue4B-4bc6A:
29.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3WZD_A_LEVA1201_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 12 LEU A  42
VAL A  50
ALA A  63
LEU A  85
CYH A 113
GLY A 116
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
None
XZN  A1317 (-3.7A)
XZN  A1317 ( 3.7A)
 0.64A 3wzdA-4bc6A:
21.2		 3wzdA-4bc6A:
27.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3WZD_A_LEVA1201_2
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		4 / 5 ILE A  84
VAL A  94
LEU A 164
ASP A 175
 None
XZN  A1317 (-4.4A)
XZN  A1317 (-4.7A)
XZN  A1317 (-3.2A)
 0.80A 3wzdA-4bc6A:
21.2		 3wzdA-4bc6A:
27.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3WZD_A_LEVA1201_2
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		4 / 5 LYS A  65
VAL A  94
LEU A 164
ASP A 175
 XZN  A1317 (-4.1A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.7A)
XZN  A1317 (-3.2A)
 0.74A 3wzdA-4bc6A:
21.2		 3wzdA-4bc6A:
27.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3WZE_A_BAXA1201_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 LEU A  42
VAL A  50
ALA A  63
LEU A  85
PHE A 112
GLY A 116
HIS A 155
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
None
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
None
 0.64A 3wzeA-4bc6A:
13.8		 3wzeA-4bc6A:
27.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AC9_C_DXCC1477_0
(MJ0495-LIKE PROTEIN)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		4 / 6 THR A 166
GLY A 115
ILE A 121
LEU A 164
 None
None
None
XZN  A1317 (-4.7A)
 0.63A 4ac9C-4bc6A:
undetectable		 4ac9C-4bc6A:
21.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ACA_C_DXCC1477_0
(TRANSLATION
ELONGATION FACTOR
SELB)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		4 / 6 THR A 166
GLY A 115
ILE A 121
LEU A 164
 None
None
None
XZN  A1317 (-4.7A)
 0.63A 4acaC-4bc6A:
undetectable		 4acaC-4bc6A:
21.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ACB_C_DXCC1477_0
(TRANSLATION
ELONGATION FACTOR
SELB)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		4 / 6 THR A 166
GLY A 115
ILE A 121
LEU A 164
 None
None
None
XZN  A1317 (-4.7A)
 0.65A 4acbC-4bc6A:
undetectable		 4acbC-4bc6A:
21.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AG8_A_AXIA2000_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 LEU A  42
VAL A  50
ALA A  63
LYS A  65
PHE A 112
GLY A 116
LEU A 164
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.1A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
 0.80A 4ag8A-4bc6A:
20.7		 4ag8A-4bc6A:
27.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AG8_A_AXIA2000_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 LEU A  42
VAL A  50
ALA A  63
VAL A  94
PHE A 112
GLY A 116
LEU A 164
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
 0.74A 4ag8A-4bc6A:
20.7		 4ag8A-4bc6A:
27.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AGD_A_B49A2000_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 11 LEU A  42
ALA A  63
VAL A  94
PHE A 112
CYH A 113
GLY A 116
LEU A 164
 XZN  A1317 (-3.6A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.5A)
XZN  A1317 (-3.7A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
 0.70A 4agdA-4bc6A:
19.9		 4agdA-4bc6A:
25.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ANQ_A_VGHA9000_1
(ALK TYROSINE KINASE
RECEPTOR)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 9 LEU A  42
VAL A  50
ALA A  63
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.52A 4anqA-4bc6A:
23.5		 4anqA-4bc6A:
27.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ANS_A_VGHA9000_1
(ALK TYROSINE KINASE
RECEPTOR)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 9 LEU A  42
VAL A  50
ALA A  63
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.53A 4ansA-4bc6A:
23.5		 4ansA-4bc6A:
27.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ASD_A_BAXA1500_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		8 / 12 LEU A  42
VAL A  50
ALA A  63
GLU A  81
LEU A  85
PHE A 112
GLY A 116
HIS A 155
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
None
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
None
 0.79A 4asdA-4bc6A:
20.6		 4asdA-4bc6A:
25.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4BKJ_A_STIA1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 12 VAL A  50
ALA A  63
GLU A  81
ILE A  84
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
None
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.86A 4bkjA-4bc6A:
20.6		 4bkjA-4bc6A:
26.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4BKJ_B_STIB1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 12 VAL A  50
ALA A  63
GLU A  81
ILE A  84
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
None
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.83A 4bkjB-4bc6A:
20.6		 4bkjB-4bc6A:
26.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4C8B_A_0LIA1000_1
(RECEPTOR-INTERACTING
SERINE/THREONINE-PRO
TEIN KINASE 2)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 ALA A  63
GLU A  81
LEU A  85
ILE A 108
HIS A 155
LEU A 164
ALA A 174
 XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
None
XZN  A1317 (-4.4A)
None
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.68A 4c8bA-4bc6A:
23.0		 4c8bA-4bc6A:
27.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4C8B_B_0LIB1000_1
(RECEPTOR-INTERACTING
SERINE/THREONINE-PRO
TEIN KINASE 2)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 ALA A  63
GLU A  81
LEU A  85
ILE A  93
HIS A 155
LEU A 164
ALA A 174
 XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
None
None
None
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.69A 4c8bB-4bc6A:
23.4		 4c8bB-4bc6A:
27.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CSV_A_STIA1265_1
(SRC-ABL TYROSINE
KINASE ANCESTOR)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 VAL A  50
ALA A  63
GLU A  81
ILE A  84
VAL A  94
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
None
XZN  A1317 (-4.4A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.74A 4csvA-4bc6A:
22.0		 4csvA-4bc6A:
27.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4KS8_A_B49A701_1
(SERINE/THREONINE-PRO
TEIN KINASE PAK 6)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 10 ALA A  63
VAL A  94
PHE A 112
GLY A 116
LEU A 164
ASP A 175
 XZN  A1317 (-3.5A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 (-3.2A)
 0.57A 4ks8A-4bc6A:
28.5		 4ks8A-4bc6A:
34.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MXO_B_DB8B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		8 / 12 LEU A  42
VAL A  50
ALA A  63
LYS A  65
VAL A  94
ILE A 108
GLY A 116
LEU A 164
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.1A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.4A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
 0.81A 4mxoB-4bc6A:
22.8		 4mxoB-4bc6A:
24.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MXX_A_DB8A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		8 / 12 LEU A  42
ALA A  63
LYS A  65
GLU A  81
VAL A  94
ILE A 108
GLY A 116
LEU A 164
 XZN  A1317 (-3.6A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.1A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.4A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
 1.06A 4mxxA-4bc6A:
22.9		 4mxxA-4bc6A:
23.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MXY_A_DB8A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		8 / 12 LEU A  42
VAL A  50
ALA A  63
GLU A  81
VAL A  94
ILE A 108
GLY A 116
LEU A 164
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.4A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
 0.96A 4mxyA-4bc6A:
23.0		 4mxyA-4bc6A:
23.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MXY_B_DB8B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		8 / 12 LEU A  42
VAL A  50
ALA A  63
LYS A  65
VAL A  94
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.1A)
XZN  A1317 (-4.4A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.80A 4mxyB-4bc6A:
22.8		 4mxyB-4bc6A:
23.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MXZ_A_DB8A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		8 / 12 LEU A  42
VAL A  50
ALA A  63
GLU A  81
VAL A  94
ILE A 108
GLY A 116
LEU A 164
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.4A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
 0.96A 4mxzA-4bc6A:
23.0		 4mxzA-4bc6A:
23.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MXZ_B_DB8B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		8 / 12 LEU A  42
VAL A  50
ALA A  63
LYS A  65
VAL A  94
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.1A)
XZN  A1317 (-4.4A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.80A 4mxzB-4bc6A:
22.8		 4mxzB-4bc6A:
23.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4O0S_A_ADNA500_1
(AURORA KINASE A)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 11 LEU A  42
GLY A  43
VAL A  50
ALA A  63
ASN A 162
LEU A 164
ASP A 175
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.9A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
None
XZN  A1317 (-4.7A)
XZN  A1317 (-3.2A)
 0.81A 4o0sA-4bc6A:
25.3		 4o0sA-4bc6A:
32.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4O0W_A_ADNA501_1
(AURORA KINASE A)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		4 / 6 LEU A  42
GLY A  43
VAL A  50
ALA A  63
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.9A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
 0.21A 4o0wA-4bc6A:
25.1		 4o0wA-4bc6A:
32.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4TWP_A_AXIA601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		9 / 12 LEU A  42
VAL A  50
ALA A  63
LYS A  65
PHE A 112
GLY A 116
ASN A 162
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.1A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
None
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.93A 4twpA-4bc6A:
22.7		 4twpA-4bc6A:
30.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4TWP_B_AXIB601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		9 / 12 LEU A  42
VAL A  50
ALA A  63
LYS A  65
PHE A 112
GLY A 116
ASN A 162
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.1A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
None
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.98A 4twpB-4bc6A:
23.1		 4twpB-4bc6A:
30.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4TYJ_A_0LIA801_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 4)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		5 / 12 ALA A  63
GLU A  81
HIS A 155
LEU A 164
ALA A 174
 XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
None
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.65A 4tyjA-4bc6A:
21.4		 4tyjA-4bc6A:
28.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U0I_A_0LIA1001_2
(MAST/STEM CELL
GROWTH FACTOR
RECEPTOR
KIT,MAST/STEM CELL
GROWTH FACTOR
RECEPTOR KIT)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 12 ALA A  63
LEU A  85
CYH A 113
GLY A 116
HIS A 155
LEU A 164
 XZN  A1317 (-3.5A)
None
XZN  A1317 (-3.7A)
XZN  A1317 ( 3.7A)
None
XZN  A1317 (-4.7A)
 0.42A 4u0iA-4bc6A:
20.8		 4u0iA-4bc6A:
29.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V01_A_0LIA1776_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		5 / 12 ALA A  63
GLU A  81
LEU A 148
HIS A 155
ALA A 174
 XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
None
None
XZN  A1317 ( 4.3A)
 0.85A 4v01A-4bc6A:
20.8		 4v01A-4bc6A:
28.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V01_B_0LIB1770_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		5 / 12 ALA A  63
GLU A  81
LEU A 148
HIS A 155
ALA A 174
 XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
None
None
XZN  A1317 ( 4.3A)
 0.78A 4v01B-4bc6A:
21.1		 4v01B-4bc6A:
28.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V04_B_0LIB1771_2
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		5 / 12 ALA A  63
GLU A  81
LEU A 148
HIS A 155
ALA A 174
 XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
None
None
XZN  A1317 ( 4.3A)
 0.89A 4v04B-4bc6A:
21.0		 4v04B-4bc6A:
28.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WA9_B_AXIB9000_1
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		8 / 12 VAL A  50
ALA A  63
LYS A  65
PHE A 112
GLY A 116
ASN A 162
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.1A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
None
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 1.13A 4wa9B-4bc6A:
22.2		 4wa9B-4bc6A:
29.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XEY_A_1N1A601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		9 / 12 LEU A  42
VAL A  50
ALA A  63
VAL A  94
ILE A 108
PHE A 112
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.77A 4xeyA-4bc6A:
22.2		 4xeyA-4bc6A:
24.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XEY_B_1N1B601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 VAL A  50
ALA A  63
ILE A 108
PHE A 112
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.62A 4xeyB-4bc6A:
21.6		 4xeyB-4bc6A:
24.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XLI_A_1N1A601_1
(NON-SPECIFIC
PROTEIN-TYROSINE
KINASE)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		8 / 12 LEU A  42
ALA A  63
LYS A  65
GLU A  81
VAL A  94
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.1A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.4A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.90A 4xliA-4bc6A:
23.4		 4xliA-4bc6A:
29.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XLI_B_1N1B600_1
(NON-SPECIFIC
PROTEIN-TYROSINE
KINASE)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		8 / 12 LEU A  42
ALA A  63
GLU A  81
VAL A  94
ILE A 108
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.4A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.84A 4xliB-4bc6A:
23.3		 4xliB-4bc6A:
29.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5AJQ_A_DB8A800_1
(SERINE/THREONINE-PRO
TEIN KINASE 10)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		8 / 12 LEU A  42
ALA A  63
PHE A 112
CYH A 113
GLY A 116
GLU A 124
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.5A)
XZN  A1317 (-3.7A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-3.3A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.47A 5ajqA-4bc6A:
35.4		 5ajqA-4bc6A:
100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5AJQ_A_DB8A800_1
(SERINE/THREONINE-PRO
TEIN KINASE 10)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		9 / 12 LEU A  42
GLY A  43
ALA A  63
LYS A  65
PHE A 112
CYH A 113
GLY A 116
LEU A 164
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.9A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.1A)
XZN  A1317 (-4.5A)
XZN  A1317 (-3.7A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.84A 5ajqA-4bc6A:
35.4		 5ajqA-4bc6A:
100.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5H2U_B_1N1B501_1
(PROTEIN-TYROSINE
KINASE 6)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 12 LEU A  42
VAL A  50
ALA A  63
GLY A 116
LEU A 164
ASP A 175
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 (-3.2A)
 0.75A 5h2uB-4bc6A:
21.5		 5h2uB-4bc6A:
27.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5H2U_B_1N1B501_1
(PROTEIN-TYROSINE
KINASE 6)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 12 LEU A  42
VAL A  50
ALA A  63
ILE A 108
GLY A 116
LEU A 164
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.4A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
 0.76A 5h2uB-4bc6A:
21.5		 5h2uB-4bc6A:
27.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5H2U_C_1N1C501_1
(PROTEIN-TYROSINE
KINASE 6)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		5 / 12 LEU A  42
ALA A  63
GLY A 116
LEU A 164
ASP A 175
 XZN  A1317 (-3.6A)
XZN  A1317 (-3.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 (-3.2A)
 0.60A 5h2uC-4bc6A:
21.3		 5h2uC-4bc6A:
27.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5H2U_C_1N1C501_1
(PROTEIN-TYROSINE
KINASE 6)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		5 / 12 LEU A  42
ALA A  63
ILE A 108
GLY A 116
LEU A 164
 XZN  A1317 (-3.6A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.4A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
 0.66A 5h2uC-4bc6A:
21.3		 5h2uC-4bc6A:
27.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HI2_A_BAXA801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 12 ALA A  63
GLU A  81
LEU A  85
CYH A 113
LEU A 148
HIS A 155
 XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
None
XZN  A1317 (-3.7A)
None
None
 0.74A 5hi2A-4bc6A:
21.9		 5hi2A-4bc6A:
27.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5L2T_A_6ZZA900_1
(CYCLIN-DEPENDENT
KINASE 6)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 12 GLY A  43
VAL A  50
ALA A  63
VAL A  94
LEU A 164
ALA A 174
 XZN  A1317 ( 4.9A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.93A 5l2tA-4bc6A:
20.7		 5l2tA-4bc6A:
28.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5MAF_A_XINA403_2
(MATERNAL EMBRYONIC
LEUCINE ZIPPER
KINASE)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		4 / 5 LEU A  85
CYH A 113
LEU A 164
ASP A 175
 None
XZN  A1317 (-3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 (-3.2A)
 0.42A 5mafA-4bc6A:
14.2		 5mafA-4bc6A:
15.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5MO4_A_NILA601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 10 LEU A  42
VAL A  50
GLU A  81
ILE A 108
PHE A 112
GLY A 116
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
 0.84A 5mo4A-4bc6A:
14.0		 5mo4A-4bc6A:
19.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5MO4_A_NILA601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 10 LEU A  42
VAL A  50
LYS A  65
ILE A 108
PHE A 112
GLY A 116
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-4.1A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
 0.71A 5mo4A-4bc6A:
14.0		 5mo4A-4bc6A:
19.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5MO4_A_NILA601_2
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 12 ALA A  63
VAL A  94
ILE A 110
HIS A 155
LEU A 164
ALA A 174
 XZN  A1317 (-3.5A)
XZN  A1317 (-4.4A)
XZN  A1317 (-3.3A)
None
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.67A 5mo4A-4bc6A:
13.9		 5mo4A-4bc6A:
19.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5OWR_A_1N1A401_1
(SERINE/THREONINE-PRO
TEIN KINASE 10)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 8 ALA A  63
GLU A  81
ILE A 110
CYH A 113
LEU A 164
VAL A 314
 XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-3.3A)
XZN  A1317 (-3.7A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.5A)
 0.42A 5owrA-4bc6A:
41.8		 5owrA-4bc6A:
100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5OWR_A_1N1A401_1
(SERINE/THREONINE-PRO
TEIN KINASE 10)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		5 / 8 ALA A  63
LYS A  65
ILE A 110
CYH A 113
LEU A 164
 XZN  A1317 (-3.5A)
XZN  A1317 (-4.1A)
XZN  A1317 (-3.3A)
XZN  A1317 (-3.7A)
XZN  A1317 (-4.7A)
 0.52A 5owrA-4bc6A:
41.8		 5owrA-4bc6A:
100.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TE0_A_XINA401_1
(AP2-ASSOCIATED
PROTEIN KINASE 1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 12 ALA A  63
GLU A  81
VAL A  94
PHE A 112
GLY A 116
LEU A 164
 XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.5A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
 0.61A 5te0A-4bc6A:
22.3		 5te0A-4bc6A:
27.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5W5V_A_ANWA701_0
(SERINE/THREONINE-PRO
TEIN KINASE TBK1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		5 / 9 LEU A  42
ALA A  63
VAL A  94
CYH A 113
GLY A 116
 XZN  A1317 (-3.6A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.4A)
XZN  A1317 (-3.7A)
XZN  A1317 ( 3.7A)
 0.80A 5w5vA-4bc6A:
4.9		 5w5vA-4bc6A:
19.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5XV7_A_EMHA705_1
(SERINE-ARGININE (SR)
PROTEIN KINASE 1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		5 / 12 LEU A  42
GLY A  43
VAL A  50
ALA A  63
ALA A 174
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.9A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 ( 4.3A)
 0.44A 5xv7A-4bc6A:
22.0		 5xv7A-4bc6A:
13.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5Y7Z_A_IREA401_0
(CYCLIN-G-ASSOCIATED
KINASE)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 LEU A  42
VAL A  50
ALA A  63
GLU A  81
CYH A 113
GLY A 116
LEU A 164
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-3.7A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
 0.71A 5y7zA-4bc6A:
23.2		 5y7zA-4bc6A:
15.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5Y7Z_A_IREA401_0
(CYCLIN-G-ASSOCIATED
KINASE)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 LEU A  42
VAL A  50
ALA A  63
GLU A  81
CYH A 113
GLY A 116
LEU A 164
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-3.7A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
 0.71A 5y7zA-4bc6A:
23.2		 5y7zA-4bc6A:
27.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5Y7Z_A_IREA401_0
(CYCLIN-G-ASSOCIATED
KINASE)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 LEU A  42
VAL A  50
ALA A  63
LYS A  65
CYH A 113
GLY A 116
LEU A 164
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.1A)
XZN  A1317 (-3.7A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
 0.84A 5y7zA-4bc6A:
23.2		 5y7zA-4bc6A:
15.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5Y7Z_A_IREA401_0
(CYCLIN-G-ASSOCIATED
KINASE)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 LEU A  42
VAL A  50
ALA A  63
LYS A  65
CYH A 113
GLY A 116
LEU A 164
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.1A)
XZN  A1317 (-3.7A)
XZN  A1317 ( 3.7A)
XZN  A1317 (-4.7A)
 0.84A 5y7zA-4bc6A:
23.2		 5y7zA-4bc6A:
27.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5YU9_A_1E8A1101_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		6 / 12 LEU A  42
GLY A  43
VAL A  50
ALA A  63
LEU A 164
ASP A 175
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.9A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.7A)
XZN  A1317 (-3.2A)
 0.64A 5yu9A-4bc6A:
20.4		 5yu9A-4bc6A:
16.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD4_A_STIA604_0
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 VAL A  50
ALA A  63
GLU A  81
VAL A  94
ILE A 108
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.70A 6hd4A-4bc6A:
21.2		 6hd4A-4bc6A:
16.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD4_A_STIA604_0
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 VAL A  50
ALA A  63
LYS A  65
ILE A  84
ILE A 108
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.1A)
None
XZN  A1317 (-4.4A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 1.11A 6hd4A-4bc6A:
21.2		 6hd4A-4bc6A:
16.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD4_A_STIA604_0
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 VAL A  50
ALA A  63
LYS A  65
VAL A  94
ILE A 108
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.1A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.78A 6hd4A-4bc6A:
21.2		 6hd4A-4bc6A:
16.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD4_B_STIB602_0
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 VAL A  50
ALA A  63
GLU A  81
VAL A  94
ILE A 108
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.69A 6hd4B-4bc6A:
21.1		 6hd4B-4bc6A:
16.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD4_B_STIB602_0
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 VAL A  50
ALA A  63
LYS A  65
ILE A  84
ILE A 108
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.1A)
None
XZN  A1317 (-4.4A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 1.14A 6hd4B-4bc6A:
21.1		 6hd4B-4bc6A:
16.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD4_B_STIB602_0
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 VAL A  50
ALA A  63
LYS A  65
VAL A  94
ILE A 108
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.1A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.78A 6hd4B-4bc6A:
21.1		 6hd4B-4bc6A:
16.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD6_A_STIA603_0
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		8 / 12 VAL A  50
ALA A  63
GLU A  81
VAL A  94
ILE A 108
PHE A 112
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.5A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.77A 6hd6A-4bc6A:
21.2		 6hd6A-4bc6A:
16.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD6_A_STIA603_0
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		8 / 12 VAL A  50
ALA A  63
LYS A  65
VAL A  94
ILE A 108
PHE A 112
LEU A 164
ALA A 174
 XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.1A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.5A)
XZN  A1317 (-4.7A)
XZN  A1317 ( 4.3A)
 0.80A 6hd6A-4bc6A:
21.2		 6hd6A-4bc6A:
16.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD6_B_STIB601_0
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 LEU A  42
VAL A  50
ALA A  63
GLU A  81
VAL A  94
PHE A 112
LEU A 164
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-3.9A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.5A)
XZN  A1317 (-4.7A)
 0.83A 6hd6B-4bc6A:
21.2		 6hd6B-4bc6A:
16.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD6_B_STIB601_0
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 LEU A  42
VAL A  50
ALA A  63
LYS A  65
ILE A  84
PHE A 112
LEU A 164
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.1A)
None
XZN  A1317 (-4.5A)
XZN  A1317 (-4.7A)
 0.95A 6hd6B-4bc6A:
21.2		 6hd6B-4bc6A:
16.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD6_B_STIB601_0
(TYROSINE-PROTEIN
KINASE ABL1)		 4bc6 SERINE/THREONINE-PRO
TEIN KINASE 10
(Homo
sapiens) 		7 / 12 LEU A  42
VAL A  50
ALA A  63
LYS A  65
VAL A  94
PHE A 112
LEU A 164
 XZN  A1317 (-3.6A)
XZN  A1317 ( 4.7A)
XZN  A1317 (-3.5A)
XZN  A1317 (-4.1A)
XZN  A1317 (-4.4A)
XZN  A1317 (-4.5A)
XZN  A1317 (-4.7A)
 0.81A 6hd6B-4bc6A:
21.2		 6hd6B-4bc6A:
16.45